LACTOLOGY FOUNDATION

Ornithine oxoglurate (ATC A05BA06) is a liver therapy agent used as an adjuvant in chronic liver disease and in patients with catabolic stress, but its safety profile in breastfeeding is poorly documented and requires a cautious, individualized risk–benefit assessment.medpedia.framar+5

Classification and general description

Ornithine oxoglurate (also known as ornithine α‑ketoglutarate, OKG or OGO) is the salt of the amino acid ornithine and alpha‑ketoglutaric acid.pubchem.ncbi.nlm.nih+1
It belongs to ATC group A05BA “drugs for liver therapy”, at the specific code A05BA06.atcddd.fhi+1

The drug is marketed in oral powder sachets for solution for nutritional support in elderly malnourished patients and as an adjunct in chronic liver disease.has-sante+1
Typical indications include chronic hepatitis, fatty liver disease, cirrhosis with latent or manifest hepatic encephalopathy, and nutritional support after trauma or in elderly patients.wikipedia+3

Pharmacology and clinical use

OGO provides ornithine, a urea‑cycle amino acid, and alpha‑ketoglutarate, a Krebs cycle intermediate and glutamine precursor.drugbank+2
By enhancing ammonia detoxification via the urea cycle and glutamine synthesis, it may reduce hyperammonemia and improve hepatic encephalopathy and nutritional status.pubmed.ncbi.nlm.nih+3

Clinical data show improvement in nutritional status in burn, trauma and elderly patients, and suggest possible benefit on hepatic encephalopathy outcomes, though evidence quality is low and heterogeneous.cochrane+1
Common therapeutic use is as an oral solution in doses around 10–30 g/day for short periods (e.g. up to three weeks) or in repeated sachets taken after meals.webmd+2

Adverse effects and contraindications

Reported adverse effects are mainly gastrointestinal, including nausea, vomiting, abdominal pain, flatulence and diarrhoea.medpedia.framar
Musculoskeletal pain and cutaneous allergic reactions have also been described.medpedia.framar

Contraindications include hypersensitivity to the active substance, renal insufficiency and hereditary fructose intolerance or other carbohydrate‑malabsorption syndromes when the formulation contains sucrose or similar excipients.base-donnees-publique.medicaments+1
Allergic reactions may be more likely in patients with aspirin allergy, and careful history taking is recommended before use.medpedia.framar

Current data do not indicate specific clinically relevant pharmacokinetic drug–drug interactions, and product information often states “no known interactions”.base-donnees-publique.medicaments+1

Dose and administration

For oral therapy, ornithine oxoglurate is supplied as powder sachets to be dissolved in plenty of liquid and taken after meals.base-donnees-publique.medicaments+1
Usual adult regimens involve 1–2 sachets up to three times daily, adjusted to clinical response, nutritional status and hepatic function.base-donnees-publique.medicaments+1

In hospital settings, higher daily doses may be used for limited durations in patients with catabolic stress (burns, trauma) or in hepatic encephalopathy, always under close monitoring.pubmed.ncbi.nlm.nih+1

Toxicological considerations

OGO combines endogenous metabolites, and at therapeutic doses systemic toxicity is generally low.pubchem.ncbi.nlm.nih+2
However, high doses may increase nitrogen load and require caution in patients with advanced hepatic failure or significant renal dysfunction.cochrane+2

Experimental and clinical literature does not suggest direct teratogenic or mutagenic effects, but robust long‑term safety data are limited.pubmed.ncbi.nlm.nih+1
Because excipients (e.g. sugars) can be clinically relevant, toxicological assessment must consider both active substance and formulation, especially in patients with inherited carbohydrate metabolism disorders.medpedia.framar+1

Lactation safety assessment

There are no dedicated pharmacokinetic or clinical studies quantifying ornithine oxoglurate transfer into human milk or its effects on breastfed infants.mayoclinic+2
General lactation guidance notes that almost any orally administered medicine appears in breast milk in small amounts, but risk is usually low unless the drug has specific toxicity or accumulates significantly.mayoclinic

For ornithine ketoglutarate, consumer‑level sources explicitly state that there is not enough reliable information on safety in pregnancy and breastfeeding and advise avoidance in these populations.webmd
A liver‑therapy product monograph (L‑ornithine‑L‑aspartate, same ATC group) similarly notes that transfer into breast milk is unknown and recommends caution.mims

Given the lack of human data for OGO, its use during breastfeeding should be approached as “unknown risk”, with preference for established alternatives whenever possible.mims+2
Risk assessment must be individualized, considering maternal hepatic disease severity, available alternative therapies, infant gestational age and comorbidities, and local specialist resources (e.g. drug‑in‑milk information centres).pmc.ncbi.nlm.nih+2

Practical toxicological‑lactational guidance

From a toxicological‑lactological standpoint, ornithine oxoglurate is best classified as “insufficient evidence for safety – use only if clearly necessary and under specialist supervision”.webmd+2
In stable chronic liver disease where safer, better‑studied options exist, postponing OGO or switching to an alternative with known lactation data is generally advisable.pmc.ncbi.nlm.nih+2

If OGO is deemed essential (e.g. refractory hepatic encephalopathy or severe malnutrition where it offers specific benefit), clinicians should:

• Use the lowest effective dose and shortest possible course.cochrane+1
• Prefer in‑hospital initiation with infant monitoring (feeding, weight gain, behaviour).infantrisk+1
• Document informed consent about the limited lactation evidence.

Consultation with a clinical pharmacologist, hepatologist and a specialist lactation information service (such as a drug‑in‑breastmilk centre) is strongly recommended before initiating therapy in breastfeeding women.infantrisk+2